All In Biotech

Drug Trial Radar · NCT00367133

Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema

A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema

Last checked: Nov 20, 2026Latest source record: Aug 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 840 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

840

Actual

Start

Jul 2004

Primary completion

May 2008

Study completion Oct 2008

Sponsor

Lead sponsor
Jaeb Center for Health ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Eye Institute (NEI); Allergan
First posted
Aug 22, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study involves the enrollment of patients over 18 years of age with diabetic macular edema(DME). Patients with one study eye will be randomly assigned (stratified by visual acuity and prior laser) with equal probability to one of the three treatment groups: 1. Laser photocoagulation 2. 1mg intravitreal triamcinolone acetonide injection 3. 4mg intravitreal triamcinolone acetonide injection For patients with two study eyes (both eyes eligible at the time of randomization), the right eye (stratified by visual acuity and prior laser) will be randomly assigned with equal probabilities to one of the three treatment groups listed above. The left eye will be assigned to the alternative treatment (laser or triamcinolone). If the left eye is assigned to triamcinolone, then the dose (1mg or 4 mg) will be randomly assigned to the left eye with equal probability (stratified by visual acuity and prior laser). The study drug, triamcinolone acetonide, has been manufactured as a sterile intravitreal injectable by Allergan. Study eyes assigned to an intravitreal triamcinolone injection will receive a dose of either 1mg or 4mg. There is no indication of which treatment regimen will be better. Patients enrolled into the study will be followed for three years and will have study visits every 4 months after receiving their assigned study treatment. In addition, standard of care post-treatment visits will be performed at 4 weeks after each intravitreal injection.

Conditions

  • Diabetic Macular Edema

Interventions

  • Standard of Care GroupProcedure

    Standard of care group: conventional treatment consisting of focal/grid photocoagulation.

  • 1mg triamcinolone acetonideDrug

    Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.

  • 4mg triamcinolone acetonideDrug

    4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years.Time frame: Baseline to 2 Years
  2. Median Change in Visual Acuity Baseline to 2 YearsTime frame: Baseline to 2 Years
  3. Distribution of Change in Visual Acuity Baseline to 2 YearsTime frame: baseline to 2 years

Locations

84 sites in 1 country. Site status is shown where the registry gives one.

  • Jones Eye Institute/University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • SCPMG Regional Offices - Kaiser Permanente

    Baldwin Park, California

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • University of California, Irvine

    Irvine, California

  • Loma Linda University Health Care, Dept. of Ophthalmology

    Loma Linda, California

  • Doheny Eye Institute

    Los Angeles, California

  • Jules Stein Eye Institute

    Los Angeles, California

  • Southern California Desert Retina Consultants, MC

    Palm Springs, California

  • West Coast Retina Medical Group, Inc.

    San Francisco, California

  • Orange County Retina Medical Group

    Santa Ana, California

  • California Retina Consultants

    Santa Barbara, California

  • Bay Area Retina Associates

    Walnut Creek, California

  • Denver Health Medical Center

    Denver, Colorado

  • Eldorado Retina Associates, P.C.

    Louisville, Colorado

  • Connecticut Retina Consultants

    New Haven, Connecticut

  • Connecticut Retina Consultants

    New Haven, Connecticut

  • Retina Group of Florida

    Fort Lauderdale, Florida

  • National Ophthalmic Research Institute

    Fort Myers, Florida

  • Central Florida Retina Institute

    Lakeland, Florida

  • Florida Retina Consultants

    Lakeland, Florida

  • Sarasota Retina Institute

    Sarasota, Florida

  • International Eye Center

    Tampa, Florida

  • Southeast Retina Center, P.C.

    Augusta, Georgia

  • Retina Consultants of Hawaii, Inc.

    ‘Aiea, Hawaii

  • Retina Associates of Hawaii, Inc.

    Honolulu, Hawaii

  • Northwestern Medical Faculty Foundation

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Illinois Retina Associates

    Joliet, Illinois

  • Raj K. Maturi, M.D., P.C.

    Indianapolis, Indiana

  • John-Kenyon American Eye Institute

    New Albany, Indiana

  • Retina and Vitreous Associates of Kentucky

    Lexington, Kentucky

  • Paducah Retinal Center

    Paducah, Kentucky

  • Maine Vitreoretinal Consultants

    Bangor, Maine

  • Elman Retina Group, P.A.

    Baltimore, Maryland

  • Wilmer Ophthalmological Institute at Johns Hopkins

    Baltimore, Maryland

  • The Retina Group of Washington

    Greenbelt, Maryland

  • Retina Consultants of Delmarva, P.A.

    Salisbury, Maryland

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • Joslin Diabetes Center

    Boston, Massachusetts

  • Kresge Eye Institute

    Detroit, Michigan

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.